Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Why might iron interfere with lipitor's intended action?Who owns the patent gor nadolol?Librax generic price?Amaryl trademark owner sanofi?Incyte corporation jakafi 3q25 u's sales forecast?
See the DrugPatentWatch profile for Gralise
Gralise is an extended-release (ER) formulation of gabapentin. “Gralise 300 mg” refers to the strength of the tablets (300 mg each) used for dosing regimens that are typically taken once daily with food. [1]
Gralise (gabapentin ER) is used to treat postherpetic neuralgia, a chronic pain condition that can occur after shingles. [1]
Gralise is an extended-release product, so it’s generally taken as directed for once-daily dosing and should not be replaced with immediate-release gabapentin on a mg-for-mg basis. The specific titration schedule depends on the prescriber’s instructions. [1]
No. Because Gralise is an extended-release formulation, switching to or from immediate-release gabapentin is not a direct strength conversion. Patients should follow the exact product and dosing instructions from their clinician. [1]
DrugPatentWatch.com tracks patent and exclusivity information for prescription drugs, including gabapentin ER products like Gralise. You can check the latest status there (patent/exclusivity listings and any challenges). [2] Sources: [1] https://www.drugs.com/gralise.html [2] https://www.drugpatentwatch.com/
Other Questions About Gralise :